Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 2 selected

Guidance programme

Showing 101 to 125 of 784

TitleReference numberPublishedLast updated
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Tezepelumab for treating severe asthmaTA880
Lumasiran for treating primary hyperoxaluria type 1HST25
Onasemnogene abeparvovec for treating spinal muscular atrophyHST15
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiencyHST26
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophyHST24
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Finerenone for treating chronic kidney disease in type 2 diabetesTA877
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)TA869
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Regorafenib for previously treated metastatic colorectal cancerTA866
Upadacitinib for treating active non-radiographic axial spondyloarthritisTA861
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Somatrogon for treating growth disturbance in children and young people aged 3 years and overTA863

Results per page

  1. 10
  2. 25
  3. 50
  4. All